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Abstract While nonsteroidal anti-inflammatory drugs have 
been shown to exert preventive ffects against the development 
of colonic tumors in humans and in chemically-induced tumors in 
animal models, the mechanism(s) involved in this phenomenon is 
unclear. We have recently demonstrated that one such agent, 
piroxleam, when supplemented (75 ppm) in the diets of rats ad- 
ministered azoxymethane, reduced the incidence of rats hearing 
tumors. To date, the effects of piroxi©am on protein kinase C, a 
family of serinelthreonine kinases which may be intimately in- 
volved in the colonic malignant ransformation process, have not 
been examined. It was, therefore, of interest o determine whether 
piroxicam altered the expression of one or more isoforms of this 
kinase in these tumors. The present studies demonstrate that 
dietary piroxicam selectively preserved the expression of protein 
kinase C-[ in azoxymethane-induced tumors; suggesting that this 
is at least one mechanism involved in this agent's chemopreventive 
actions in this organ. 
Key words: Signal transduction; PKC; 
Chemical carcinogenesis; Large bowel; 
Nonsteroidal nti-inflammatory agent 
mechanism(s) involved in these chemopreventive actions of 
NSAIDs, however, remain unclear and controversial [11]. 
In this regard, there are several lines of evidence which indi- 
cate that alterations inthe activity and/or the expression of one 
or more isoforms of protein kinase C (PKC) may be intimately 
involved in the colonic malignant transformations process(es) 
in man and experimental animals [12-17]. To date, however, the 
effects of NSAIDs on PKC have not been examined. Recently, 
in agreement with prior studies [8], our laboratory [10] has 
demonstrated that dietary supplementation with piroxicam 
(75 ppm) significantly reduced the incidence of rats bearing 
tumors as well as tumor size in the azoxymethane (AOM)- 
model of experimental colonic tumorigenesis. In the present 
experiments, therefore, it was of interest to examine and com- 
pare the protein expression of several PKC isoforms in these 
colonic tumors from animals treated with AOM alone, or 
treated with AOM and supplemented with piroxicam in their 
diet. 
2. Materials and methods 
1. Introduction 
Colorectal cancer is a major cause of morbidity in the United 
States [1]. Despite advances in the fields of surgery, radiother- 
apy and chemotherapy, cure rates for this disease(s), unfortu- 
nately, have not significantly improved uring the past several 
decades [1]. Based on these considerations, several potential 
anticarcinogens have been studied in an effort to prevent col- 
orectal carcinoma. Nonsteroidal anti-inflammatory drugs 
(NSAIDs) ~, including piroxicam, aspirin, sulindac and in- 
domethacin, have shown promise for this purpose. A number 
of epidemiological studies in humans [2-4], interventional in- 
vestigations in patients with familial polyposis [5-6], as well as 
animal studies using various models of colonic carcinogenesis 
[7-10], have suggested that NSAIDs reduce the risk of develop- 
ing colorectal cancer and/or its associated mortality. The exact 
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As recently described in detail [10], weanling male albino Fisher 
(F344) rats, initially weighing 90-130 g, were randomly assigned into 
groups fed an AIN-76 standard iet (Bio-serve Co., Frenchtown, N J) 
with or without supplemental piroxicam (75 ppm, Sigma Chemical Co., 
St. Louis, MO). Two weeks after being placed on their diets, one-half 
the rats in each group were s.c. injected with AOM (15 mg/kg body 
wt/week) or vehicle (saline) for 2 weeks and then maintained on their 
respective diets for an additional 28 weeks. At that time, the animals 
were sacrificed, macroscopic tumors excised and harvested individu- 
ally, and sections of each tumor were fixe0 in formalin and subjected 
to histological examination [10]. Homogenates ofthe remaining portion 
of each tumor were prepared by sonication i SDS containing buffer 
and proteins assayed using a previously described method [18]. Proteins 
(,,,20/~g) were resolved by SDS.PAGE with a 10% separating gel, trans- 
ferred to PVDF membranes (Millipore Co., Bedford, MA) and probed 
with isoform specific antibodies, i.e. monoclonal anti-PKC-a ntibodies 
(Upstate Biotechnology, Lake Placid, NY) and polyclonal ntipeptide 
antibodies toPKC-8, PKC-e and PKC-~ (Gibco BRL, Gaithersburg, 
MA) as previously described [19]. The major immunoreactive band to 
PKC-~' antisera was a protein with Mr 78,000. Inconsistently, and only 
with prolonged exposure of the xerograms, we also observed a second 
band with Mr 80,000 that comigrated with PKC-a as previously de- 
scribed [20]. PKC-~" was identified as the component with M~ 78,000 
which we had previously shown did not redistribute in response toacute 
treatment of colonocytes with TPA [21]. Furthermore, the im- 
munoreactivity of this band with PKC-~' antisera was abolished by 
preincubation f the antisera with the g-specific mmunizing peptide. 
Quantitative PKC-~' protein expression reflects the 78,000 Da compo- 
nent only. Secondary antibodies were detected with an enhanced chem- 
iluminescence system (Amersham Co., Arlington Heights, IL), and 
quantitated by scanning densitometry aspreviously described [19]. 
Data was expressed asmeans + S.D. and analyzed for statistical signif- 
icance by the Student's t-test for unpaired samples [22]. 
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3. Results 
3.1. The effects of AOM and piroxicam on colonic expression of 
PKC isoforms 
In agreement with prior studies from our laboratory [21], 
normal rat colonocytes possessed PKC<z, PKC-/~, PKC-6 and 
PKC-~. In vehicle-treated animals, dietary supplementation 
with piroxicam did not significantly alter the expression of any 
of the isoforms in these cells (data not shown). As shown in Fig. 
l, however, the expression of PKC-o~ and PKC-/~ were de- 
creased, i.e. 'down-regulated', while PKC-f was unchanged, in
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Fig. I. Effects of piroxi~un supplementation on PKC isoform expres- 
sion in AOM-induced tumors. (A) Representative mmunoblots ofco- 
lonic home.narcs (20 pg) from three separate control rats, or AOM- 
induced tumors, probed with specific antibodies to the indicated PKC 
isoforms, (B) Quantitative densitometry of PKC isoform expression i  
AOM-induced tumors from animals on the AIN diet alone, or the 
piroxicam-supplemented diet. Data (mean :t: S,D.) is expressed as% of 
control with analysis of 5--7 tumors par group, a, P < 0.05, compared 
with appropriate controls (colonocytes from vehicle-treated animals on 
either an AIN diet alone, or one supplemented with piroxicam). 
(b) P < 0.05, compared with PKC-~ expression i AOM-induced tu- 
mors from rats on a diet with no piroxicarn supplementation. Note, 
there was no significant difference in PKC~'expression between control 
values and AOM-induced tumors from the piroxicam supplemented 
group (P = 0.66, unpaired Student's t-test). 
AOM-induced colonic tumors harvested from animals regard- 
less of whether their diets were or were not supplemented with 
piroxicam. As can also be seen in this figure, while the expres- 
sion of PKC-~' (Mr 78,000 component) was also found to he 
down-regnlated in tumors of animals fed the control diet, the 
expression of this isoform was found to be preserved in AOM- 
induced tumors of animals fed the piroxicam supplemented 
dietary regimen. 
As noted previously [10], both adenomas and carcinomas 
were present in the AOM-treated groups fed an unsupple- 
mented or piroxicam supplemented diet. In the present studies, 
however, there where no significant differences in the total 
expression of any of the PKC isoforms in the carcinomas 
(2 analyzed in each group) compared to the adenomas (3-5 
analyzed in each group) (data not shown). 
4. Diseuuion 
The mechanism(s) by which NSAIDs inhibit the develop- 
ment of colonic tumors in animal models of chemically-induced 
carcinogenesis, as well as perhaps in man, are presently contro- 
versial and currently the subject of intense investigation. Poten- 
tial mechanisms, todate, which have been postulated to explain 
the effects of these agents' chemopreventive effects in this organ 
include: (i) reduction in prostagiandin synthesis via inhibition 
of cyclooxygenase(s) activity [8,11]; (ii) inhibition of cellular 
proliferation [I I]; (iii) alterations in immunomodulatory cellu- 
lar events [I 1,23]; and (iv) changes in the regulation of signal 
transduction events [11]. In this regard, evidence has accumu- 
la~'ed for [8,11,24,25] and against [7,26] the possibility that these 
agents prevent colon cancer by inhibiting prostaglandin synthe- 
sis. Recent preliminary studies in cultured cells [27], as well as 
by our laboratory in the AOM model of experimental colonic 
carcinogenesis [28], argue against effects of these agents on 
cellular proliferation being involved in this phenomenon. Our 
laboratory has, however, recently demonstrated that dietary 
piroxicam supplementation (75 ppm) can upregulate the ex- 
pression of MHC class I and II antigens in premalignant colon- 
ocytes in the aforementioned xperimental cancer model, sug- 
gesting that piroxicam-induced immunomodulatory events 
may, at least in part, explain its zhemopreventive actions in the 
rat colon [23]. 
The results of the present studies indicate that dietary pirox- 
icam supplementation may have an additional chemoprotective 
mechanism of action, i.e. this dietary regimen was found to 
selectively preserve the expression of PKC-~" in AOM-induced 
tumors compared to its loss in tumors from AOM-treated ani- 
mals maintained on a non-supplemented diet. In this regard, it 
bears emphasis that in preliminary studies [29] we have also 
noted a similar effect of ursodeoxycholic a id, another structur- 
ally unrelated chemopreventive agent [10], on the preservation 
of PKC-~" expression in tumors in this model. It is, therefore, 
possible that this finding may have more general import with 
respect to ¢hemoprevention f colonic carcinogenesis. Further 
studies, particularly in premalignant colonocytes of animals 
treated with AOM alone, or with dietary piroxicam, will there- 
fore be of interest. 
PKC-~" is a member of the Ca2*-insensitive group of PKC 
isoforms [30]. Moreover, it is also phorbol ester-insensitive in 
many cell types [30]. The present findings with respect o this 
PKC isoform are of interest since there is now accumulating 
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evidence that PKC-~" may play a key role in cell growth, differ- 
entiation and possibly malignant ransformation. In this re- 
gard, PKC-~" can be activated by phosphoinositol 3,4,5-tris- 
phosphate, indicating that this isoform is involved in signalling 
cascades of growth factors and oncogenes [31]. PKC-~" has also 
recently been implicated in the inhibition of intestinal cellular 
growth and the induction of differentiation [32], as well as 
shown to be essential in the cellular maturation of Xenopus 
oocytes [33]. It bears emphasis that in these studies piroxicam 
supplementation was associated with preservation of PKC-~', 
a potential growth-limiting isoform, and a decrease in tumor 
size as well as a decrease in incidence of rats bearing tumors 
[10]. This suggests that piroxicam, perhaps through PKC-~', 
may play important roles both to inhibit tumor initiation (de- 
creased incidence of tumor-bearing rats) and promotion (de- 
creased tumor size). In addition, our laboratory has recently 
shown that PKC-~" was the only PKC isoform constitutively 
expressed in the nuclei of CaCo-2 cells, a cell line widely used 
to investigate intestinal cell growth and differentiation, suggest- 
ing that this isoform may be involved in the modulation of gene 
expression [34]. Recently, in fact, PKC-~ has been shown to be 
critical to the activation of the nuclear transcription factor, 
NF-KB [35]. Further studies on the effects of piroxicam on 
PKC-~', and its role in this NSAiD's chemopreventive actions 
in the colonic malignant transformation process(es) will, there- 
fore, be of interest. 
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